Carbylan Therapeutics, Inc.   Report issue

For profit Phase 3
Founded: Palo Alto CA United States (2004)
Status: Acquired by KalVista Pharmaceuticals, Ltd. (2016) → now Merck (2017)

Organization Overview

First Clinical Trial
2014
NCT02022930
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1